The historical rank and industry rank for Progenics Pharmaceuticals's Net Margin % or its related term are showing as below:
PGNX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -162.84 * Ranked among companies with meaningful Net Margin % only.
Progenics Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Progenics Pharmaceuticals's Net Margin %
For the Biotechnology subindustry, Progenics Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Progenics Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Progenics Pharmaceuticals's Net Margin % falls into.
Progenics Pharmaceuticals Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Progenics Pharmaceuticals (NAS:PGNX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Progenics Pharmaceuticals Net Margin % Related Terms
Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PGNX has been successfully added to your 